{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:58:24Z","timestamp":1770965904256,"version":"3.50.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,31]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Presented are results from the phase 2 dose-expansion study of the combination of carfilzomib, lenalidomide, and dexamethasone (CRd). CRd was well tolerated with robust, rapid, and durable responses.<\/jats:p>","DOI":"10.1182\/blood-2013-07-511170","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T05:34:43Z","timestamp":1378532083000},"page":"3122-3128","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":114,"title":["Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma"],"prefix":"10.1182","volume":"122","author":[{"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California, San Francisco Medical Center, San Francisco, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Kavalerchik","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, South San Francisco, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, South San Francisco, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111817070391900_B1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"9594","key":"2019111817070391900_B2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2019111817070391900_B3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"9758","key":"2019111817070391900_B4","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"2019111817070391900_B5","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"34","key":"2019111817070391900_B6","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma.","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111817070391900_B7","doi-asserted-by":"crossref","first-page":". Abstract 3049","DOI":"10.1182\/blood.V116.21.3049.3049","article-title":"Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed\/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up [abstract].","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111817070391900_B8","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111817070391900_B9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"14","key":"2019111817070391900_B10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111817070391900_B11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2019111817070391900_B12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib.","volume":"158","author":"Vij","year":"2012","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111817070391900_B13","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma.","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111817070391900_B14","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","article-title":"A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.","volume":"18","author":"Alsina","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111817070391900_B15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111817070391900_B16"},{"issue":"8","key":"2019111817070391900_B17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111817070391900_B18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111817070391900_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2962.2962","article-title":"A phase 2 study of prolonged carfilzomib therapy in patients with multiple myeloma previously enrolled in carfilzomib clinical trials [abstract].","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111817070391900_B20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111817070391900_B21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"2019111817070391900_B22","article-title":"Common Terminology Criteria for Adverse Events, Version 3.0: DCTD, NCI, NIH.","author":"Cancer Therapy Evaluation Program","year":"2006"},{"issue":"18","key":"2019111817070391900_B23","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111817070391900_B24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"18","key":"2019111817070391900_B25","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"2019111817070391900_B26","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies [published online ahead of print August 9, 2013].","author":"Siegel","journal-title":"Haematologica"},{"issue":"21","key":"2019111817070391900_B27","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111817070391900_B28","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111817070391900_B29","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"2019111817070391900_B30","author":"Moreau"},{"issue":"9","key":"2019111817070391900_B31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"2019111817070391900_B32","author":"Korde"},{"key":"2019111817070391900_B33","author":"Stadtmauer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/18\/3122\/1370649\/3122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/18\/3122\/1370649\/3122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:07:14Z","timestamp":1574114834000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/18\/3122\/31803\/Phase-2-doseexpansion-study-PX171006-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,10,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-07-511170","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}